Abstract YO18
Case summary
Case Details - A 47-year-old female, a known case of multicentric Glioblastoma multiforme (grade four) who had received concurrent chemoradiotherapy followed by palliative Temozolomide on tapering doses of Levetiracetam and had been commenced on Phenytoin presented (during the peak of the second wave of Pandemic) with complaints of new-onset maculopapular lesions involving legs, arms, and lower back. She subsequently developed a worsening Rash with the development of vesico-bullous lesions, oral mucosal lesions, acral involvement, and systemic symptoms (Fever) 2 days later. Arrangements were made to obtain a Tele Dermatology consult (from a Private setting) following which a diagnosis of SJS TENS Overlap was made. A consult with the Medical Oncology department was sought in order to provide ICU admission which was refused. She was subsequently admitted under Palliative Medicine after obtaining high-risk consent. Her lesions regressed with supportive management comprising Cyclosporin, and intravenous antibiotics, however, her general condition deteriorated. She was discharged as she had expressed a wish to meet her mother (at home). However, she was unable to obtain a fitness for Air travel. She was re-admitted and re-started on supportive treatment (symptom-directed medications via intravenous route). A subcutaneous line was inserted in the anterior chest wall and pre-filled syringes containing essential pain medication, anti-seizure medication (sc bolus levetiracetam), and dexamethasone for three days were provided to the Patient’s husband who had volunteered to take her back home via Train.
Discussion - Important Issues included Logistical - Lack of infrastructure, Medical - use of boluses of subcutaneous medication at end of life (without syringe drivers).
Conclusion - Practical Issues related to Travel, Finances, and Continuity of care may assume more importance than Spirituality underlining the importance of formulating a comprehensive management plan most suited to the Patient and their Family members.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
419P - Breast arterial calcifications on mammogram and its clinical implications
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06
420P - Predictive factors of post-operative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis: A retrospective cohort study
Presenter: Chito Cabiling
Session: Poster viewing 06
421P - The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Presenter: Deniz Can Guven
Session: Poster viewing 06
422P - Molecular mechanism in prostate cancer with TP53 mutation
Presenter: Bin Hu
Session: Poster viewing 06
423P - Maintaining a national essential medicine list for cancer in Malaysia: Where do we stand?
Presenter: David Lee
Session: Poster viewing 06
424P - The Storm: Paraneoplastic leucomoid reaction - A bad prognostic factor
Presenter: Abdullah Al Mamun Khan
Session: Poster viewing 06
425P - Preliminary study: Assessment of public trust in traditional medicine and medical treatment in cancer patients in Indonesia - Study validity and reliability of the Universitas Sebelas Maret Trust and readiness assessment for cancer patients (UNS – TRAfCP35) questionnaire
Presenter: Widyanti Soewoto
Session: Poster viewing 06
426P - Safety of Sputnik V COVID-19 vaccine in cancer patients receiving chemotherapy: An observational study
Presenter: Alexey Rumyantsev
Session: Poster viewing 06
427P - Oncology combination therapies in Asia-Pacific markets: What are the current access challenges?
Presenter: Gayathri Kumar
Session: Poster viewing 06
428P - Clinical characteristics, laboratory parameters, and hospital outcomes of COVID-19 among patients with and without cancer: A retrospective cohort study
Presenter: PRASHANT SIROHIYA
Session: Poster viewing 06